Johnson & Johnson Challenges US Government's Medicare Drug Price Negotiation Plans

Johnson & Johnson has filed a lawsuit against the Biden administration over Medicare's new powers to negotiate drug prices, becoming the third pharmaceutical company to challenge the provision. The lawsuit argues that the Medicare negotiations violate the First and Fifth Amendments of the U.S. Constitution. J&J's complaint seeks to block the U.S. Health and Human Services Department from compelling the company to participate in the program, claiming that it threatens innovation and patients' access to transformative therapies. The policy, passed in 2022, aims to make drugs more affordable for older Americans but may reduce pharmaceutical industry profits.